FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry. A method for identifying SARS-CoV-2 virus in a sample, which includes the following steps is described: (a) sample preparation of a biological sample using the enzyme trypsin to hydrolyze proteins and obtain a mixture of polypeptides; (b) mass spectrometric analysis of the resulting mixture of polypeptides in order to identify at least two peptides selected from SEQ ID NO: 1-19; (c) if at least two peptides having the sequence SEQ ID NO: 1-19 are detected in the sample, at least one of which is a peptide selected from: SEQ ID NO: 1, SEQ ID NO: 3 - SEQ ID NO: 9, SEQ ID NO: 12 - SEQ ID NO: 19, SARS-CoV-2 virus in the sample is considered to be identified. The invention solves the problem of accelerating and increasing the reliability of the procedure for identifying the SARS-CoV-2 virus in patients. The problem is solved by the proposed method, which consists in identifying the SARS-CoV-2 virus using mass spectrometric analysis based on the developed panel of N-protein peptides (nucleocapsid).
EFFECT: accelerating and increasing reliability of the procedure for identifying the SARS-CoV-2 virus in patients.
6 cl, 5 dwg, 1 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS | 2021 |
|
RU2763001C1 |
ADVANCED CORONAVIRUS VACCINE | 2022 |
|
RU2816182C2 |
MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
HUMANIZED MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO RBD S OF THE PROTEIN OF THE SARS-COV-2 VIRUS, AGENT AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS-COV-2 VIRUS | 2021 |
|
RU2765731C1 |
METHOD FOR ASSESSING THE RISK OF DEVELOPING ALZHEIMER'S DISEASE USING A PANEL OF BLOOD PROTEINS | 2021 |
|
RU2794040C1 |
RECOMBINANT VACCINE STRAIN FOR LIVE INTRANASAL VACCINE PROVIDING COMBINED PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS | 2022 |
|
RU2782531C1 |
Authors
Dates
2021-05-26—Published
2021-02-08—Filed